Myxofibrosarcoma Following Chemotherapy and Radiotherapy for Hodgkin’s Lymphoma: Case Study and Review

Vallejo-Benítez Ana, Rodriguez-Zarco Enrique, Pabón-Carrasco Sara, Pereira-Gallardo Sofía, Villar-Rodríguez Jose Luis and González-Cámpora Ricardo

Hospital Universitario Virgen Macarena, Spain

*Corresponding author: Vallejo-Benítez Ana, Hospital Universitario Virgen Macarena, Spain, Tel: 34955008000; E-mail: anavalben@gmail.com

Introduction
Radiotherapy (RT) has become a basic tool in cancer treatment; the vast majority of cancer patients receive RT at some point in the course of their disease. The development of radiation-induced sarcoma during treatment is rare (0.035%-0.8%) [1,2]. The incidence of head and neck carcinomas and sarcomas is around 0.70% (3-5). Most published reports deal with secondary tumors following treatment for breast cancer, lymphoma and cancer of the genitourinary system [2,4,6-8]. The most common histological subtypes are pleomorphic malignant fibrous histiocytoma (high-grade undifferentiated pleomorphic sarcoma), osteosarcoma, fibrosarcoma, angio-lymphosarcoma and a number of poorly-defined lesions grouped under the generic heading spindle-cell sarcoma [1-6,9].

A review of the literature reveals only three reports of malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin’s lymphoma [2,9-13]; its incidence is therefore not clearly established. The authors report on a medium-grade soft-tissue myxofibrosarcoma (myxoid malignant fibrous histiocytoma) in a patient who had received radiotherapy and chemotherapy twenty-six years earlier for nodular sclerosing Hodgkin’s lymphoma.

Case Report
A 61-year-old man consulted the cancer unit because of a lesion on the left side of the neck, of six weeks' standing. Patient history included a nodular sclerosing Hodgkin's lymphoma in the mediastinum, diagnosed 26 years earlier and treated with mantle radiotherapy and neck irradiation (45 Gy) plus 8 cycles of chemotherapy (C-MOPP).

CT scan revealed a lesion in the left paravertebral muscle region, with loss of fat plane and a focal heterogeneous increase in contrast uptake. Neither the paravertebral muscles nor the sternocleidomastoid muscle were affected. Maximum width on cross sections was 3.3 × 5 cm, and maximum craniocaudal length was 5.5 cm. (Figure 1).

Fine-needle aspiration biopsy (FNAB) revealed two clearly-defined cell populations (spindle cells and occasionally-binuclear polygonal cells) embedded in a myxoid matrix with collagenized stromal tissue (Figure 2). The diagnosis was sarcoma consistent with myxofibrosarcoma; the tumor was removed and referred for histological examination. The tumor mass weighed 90 g and measured 6 × 5 × 4.5 cm and the histological examination revealed a grade-II superficial malignant myxoid spindle-cell tumor displaying a multinodular growth pattern. Immunohistochemical staining was positive for CD34 and negative for smooth muscle actin and desmin.

Conclusions: Given the increasing use of adjuvant therapies, particularly in the early stages of cancer, patients should be closely monitored to ensure detection of radiation/chemotherapy-induced sarcomas.
necrosis, though extensive, accounted for <50% of the lesion (Figures 4 and 5). The tumor extended to the surgical margin over 15% of its perimeter. Immunohistochemical analysis revealed diffuse positive staining for CD34 and focal positive staining for smooth muscle actin; staining was negative for desmin, CD31 and S-100 protein. The proliferation index (Ki-67 expression) in hypercellular areas was 10-15%. The tumor was diagnosed as a grade II myxofibrosarcoma (myxoid malignant fibrous histiocytoma).

The patient underwent adjuvant external radiotherapy to the surgical bed (55 Gy) and at the last check-up, 13 months later, showed no signs of local recurrence or metastasis.

Discussion

In the 1960s, radiotherapy alone was the standard treatment for early-stage Hodgkin's lymphoma (HL). In the 70s and 80s, however, it
became apparent that HL patients treated with radiotherapy were at greater risk of developing secondary malignancies than the general population [10,11]. From the 1990s onwards, therefore, it was recommended that patients with early-stage HL should receive induction chemotherapy followed by radiotherapy. However, secondary malignancies have also been reported in HL patients undergoing this combined treatment (chemotherapy with alkylating agents, radiotherapy to both sides of the diaphragm, and relatively high radiotherapy doses in this setting), although the incidence is lower than in patients receiving radiotherapy alone [10].

Secondary malignancies in HL patients have traditionally been divided into three major categories: leukemias, non-Hodgkin’s lymphomas (NHL) and solid tumors. The risk of leukemia is linked to chemotherapy and alkylating agents, and is dose-dependent. The increased risk of NHL may be related to treatment-induced immune suppression (radiotherapy/chemotherapy) or may be part of the natural history of HL, and especially of lymphocyte-predominant HL [12]. At present, due to the prolonged survival of HL patients, solid tumors have become the major subtype of secondary malignancy. They typically develop >10 years after the initial treatment [12,13], and the risk persists for over 30 years. The current risk (±standard deviation) of developing a secondary malignancy after 15 years (with the exception of basal cell carcinoma) in radiation-treated HL patients is 9.9% (±2.8), compared with 1.8% (±1.8) for patients treated with chemotherapy, whilst the risk in patients undergoing combined chemotherapy/radiotherapy is 12.9% (±2.9%) [13].

The diagnosis of radiation-induced sarcoma is based on the following criteria, set out by Cahen in 1948: a) prior history of radiation exposure and existence of a latency period; b) occurrence of the sarcoma in or near the field of radiation; and c) histological confirmation of a sarcoma that is different from the primary cancer [1].

The length of time required between radiation exposure and sarcoma formation is one of the most widely-debated criteria: some authors suggest a minimum latency period as short as one month, [1,5], although most tend to think in terms of several years [1-6,9,10,12,13].

A review of the literature reveals only three reports of malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin’s lymphoma (Table 1). Saggia et al. [13,14] reported a high-grade pleural sarcoma following a latency period of 15 years, while Nonaka et al. [9] noted a case of inflammatory malignant fibrous histiocytoma of the anterior chest wall 18 years after the patient received radiotherapy alone. Mandal et al. [2] reported on a patient with a history of tumor recurrence, treated with chemotherapy and radiotherapy, who developed a malignant fibrous histiocytoma of the knee 21 years after treatment was started. In the present case, a grade II myxofibroma was found in a patient treated for HL 26 years earlier, with radiotherapy and chemotherapy. In all four cases, the radiation dose varied between 40 and 45 Gy, and the latency period ranged from 15 and 26 years.

### Table 1: Malignant fibrous histiocytomas following radiotherapy/chemotherapy for Hodgkin's Lymphoma.

| Author | Saggia et al [14] | Nonaka et al [10] | Mandal et al [2] | Present case 2010 |
|--------|-------------------|-------------------|------------------|------------------|
| Age/Sex | 51/M              | 59/F              | 42/F             | 61/M             |
| Diagnosis | High-grade pleural sarcoma | Inflammatory MFH | MFH | Grade II myxofibrosarcoma (myxoid MFH) |
| IHC profile | CD34 (+), CK, EMA, Calretinin and S-100 (-) | Vimentin (+), SMA, Desmin, S-100, EMA, CK and CD45 (+) | CD68 and vimentin (+), SMA, S-100 and desmin (-) | CD34 (+) and focal SMA (+), Desmin, myoglobin, CD-31 and S-100 (-) |
| Location | Pleura            | Chest wall        | Right knee       | Left side of neck |
| HL | Stage IIIA | (No data) | Lymphocyte-depletion HL (inguinal) | Stage III |
| HL Treatment: Radiotherapy (RT)/Chemotherapy (CT) | RT: 40Gy + CT: MOPP (3 cycles) | RT to neck (54Gy), mediastinum (41Gy) and para-aortic region (40Gy) | -MOPP (4 cycles), -MOPP (6 cycles), -RT right tibia (44Gy), -RT right humerus (44Gy), +CT (6 cycles ABVD) | Mantle RT with neck irradiation (45Gy) + CT: C-MOPP (8 cycles) |
| Latency Period (YEARS) | 15 | 18 | 21 | 26 |
| Sarcoma Treatment | CT (Iphosphamide and epirubicin) | Surgical excision | Patient abandoned | Surgical excision + RT (55Gy) |
| Evolution | Death at 5 months | Death at 64 days | Unknown | No metastasis or local recurrence |

Generally speaking, the prognosis for radiation-induced sarcomas is worse than that of other sarcomas at a similar stage, because they tend to be radiation-resistant. However, a favorable response to radiotherapy is reported in many cases, as here. The effects of

---

Citation: Ana VB, Enrique RZ, Sara PC, Sofia PG, Jose Luis VR, et al. (2016) Myxofibrosarcoma Following Chemotherapy and Radiotherapy for Hodgkin's Lymphoma: Case Study and Review. J Clin Case Rep 6: 816. doi:10.4172/2165-7920.1000816
chemotherapy are equally controversial [2,4,9]. Given the likelihood of local recurrence and remote metastasis, prolonged close monitoring of these patients is essential to ensure early detection and enable full surgical removal of the tumor.

References

1. Cha C, Antonescu CR, Quan ML, Maru S, Brennan MF (2004) Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg 239: 903-909.
2. Mandal S, Mandal AK (2007) Malignant fibrous histiocytoma following radiation therapy and chemotherapy for Hodgkin’s lymphoma. Int J Clin Oncol 12: 52-55.
3. Chen YW, Tu HF, Wu TH, Lo WL, Chang CS, et al. (2008) Sarcomas and sarcomatoid tumor after radiotherapy of oral squamous cell carcinoma: analysis of 4 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105: 65-71.
4. Lagrange JL, Ramaioli A, Chateau MC, Marchal C, Resbeut M, et al. (2000) Sarcoma after radiation therapy: retrospective multinational study of 80 histologically confirmed cases. Radiation Therapist and Pathologist Groups of the Fédération Nationale des Centres de Lutte Contre le Cancer. Radiology 216: 197-205.
5. Pfeiffer J, Boedeker CC, R Siddar G, Maier W, Kayser G (2006) Radiation-induced leiomyosarcoma of the oropharynx. Diagn Pathol 1: 22.
6. Orosz Z, Rohonyi B, Luksander A, Szántó J (2000) Pleomorphic liposarcoma of a young woman following radiotherapy for epithelioid sarcoma. Pathol Oncol Res 6: 287-291.
7. Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56: 83-88.
8. Davis RH (2004) Production and killing of second cancer precursor cells in radiation therapy: in regard to Hall and Wuu (Int J Radiat Oncol Biol Phys 2003;56:83-88). Int J Radiat Oncol Biol Phys 59: 916.
9. Alm El-Din MA, El-Badawy SA, Taghian AG (2008) Breast cancer after treatment of Hodgkin’s lymphoma: general review. Int J Radiat Oncol Biol Phys 72: 1291-1297.
10. Nonaka M, Kadokura M, Ohkubo F, Kushihashi T, Kunimura T, et al. (2001) Post radiation inflammatory malignant fibrous histiocytoma arising from the chest wall. Ann Thorac Cardiovasc Surg 7: 371-374.
11. Chronowski GM, Wilder RB, Levy LB, Atkinson EN, Ha CS, et al. (2004) Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol 27: 73-80.
12. Yahalom J (2009) Role of radiation therapy in Hodgkin’s lymphoma. Cancer J 15: 155-160.
13. Ng AK, Mauch PM (2009) Late effects of Hodgkin’s disease and its treatment. Cancer J 15: 164-168.
14. Saggia C, Forti G, Biaggi G, Lattuada S, Santagostino A, et al. (2004) Two cases of secondary soft tissue sarcomas after radiotherapy and radiochemotherapy. Tumori 90: 622-624.